Disease · HP_0001623
Breech presentation
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. Breech presentation. Diseases, record HP_0001623. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001623
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Name
- Breech presentation
- Open Targets ID
- HP_0001623
- Other names
- Breech presentation at birth, Feet or buttocks of fetus positioned near opening of uterus, Feet or buttocks of foetus positioned near opening of uterus
- Highest stage of its drugs
- Phase 3, for 4 of its 6 drugs, from ClinicalTrials.gov
Source Open Targets
Drugs6
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| BUPIVACAINE | CHEMBL1098 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MIDAZOLAM | CHEMBL655 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROUS OXIDE | CHEMBL1234579 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| OXYGEN | CHEMBL1234886 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NITROGLYCERIN | CHEMBL730 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 3 | 3 | 2 | Drugs and targets |
| TERBUTALINE | CHEMBL1760 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
Targets21
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| ADRB2 | Beta-2 adrenergic receptor | 1 | Beta-2 adrenergic receptor agonist | Phase 2/3 | https://conductscience.org/library/genes/154 | Drugs and targets |
| GABRA1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2554 | Drugs and targets |
| GABRA2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2555 | Drugs and targets |
| GABRA3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2556 | Drugs and targets |
| GABRA4 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2557 | Drugs and targets |
| GABRA5 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2558 | Drugs and targets |
| GABRA6 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2559 | Drugs and targets |
| GABRB1 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2560 | Drugs and targets |
| GABRB2 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2561 | Drugs and targets |
| GABRB3 | GABA-A receptor; anion channel | 1 | GABA-A receptor; anion channel positive allosteric modulator | Phase 3 | https://conductscience.org/library/genes/2562 | Drugs and targets |
1 to 10 of 21
See all 21 targetsTrials7
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01991743 | A Trial Comparing Combined Spinal- Epidural Dosing Strategies for External Cephalic Version | Not applicable | 240 | 2020-01-06 | Pregnancy, Pain | BUPIVACAINE | Its record names the disease | ClinicalTrials.gov |
| NCT02115256 | Study to Evaluate is ECV Success is Improved and the Side Effects Reduced With the Use of IV NTGL Versus Terbutaline | Phase 2/3 | 6 | 2017-06-14 | External Cephalic Version | TERBUTALINE | Its record names the disease | ClinicalTrials.gov |
| NCT02801201 | Impact of Analgesia on Success of External Version: Comparison of Spinal Anesthesia Versus Sedation | Phase 3 | 186 | Breech Presentation | BUPIVACAINE, MIDAZOLAM | Its record names the disease | ClinicalTrials.gov | |
| NCT01948115 | Evaluation of the Efficacy and Safety of an Equimolar Mixture of Oxygen and Nitrous Oxide in External Cephalic Version (ECV) | Phase 3 | 150 | Breech Presentation in Pregnancy | NITROUS OXIDE, OXYGEN | Its record names the disease | ClinicalTrials.gov | |
| NCT00119184 | Spinal Analgesia Versus No Analgesia: Study for External Cephalic Version | Phase 1 | 140 | Breech Presentation | BUPIVACAINE | Its record names the disease | ClinicalTrials.gov | |
| NCT00896311 | Intravenous (IV) Nitroglycerin for Versions in Nulliparous Women | Not applicable | 82 | Breech Presentation, Complication of Pregnancy | NITROGLYCERIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00901758 | Intravenous (IV) Nitroglycerin for Versions in Multiparous Women | Not applicable | 44 | Breech Presentation, Pregnancy Complication | NITROGLYCERIN | Its record names the disease | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Successful Version of the Fetus Into the Vertex Position | 3 of 3 | 0 of 2 | 5 | NCT02115256 | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Need for Cesarean Delivery | 0 of 3 | 0 of 2 | 5 | NCT02115256 | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Tachycardia | 2 of 3 | 0 of 2 | 5 | NCT02115256 | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: deaths from any cause | 0 of 3 | 0 of 2 | 5 | NCT02115256 | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: Hypotension | 2 of 3 | 1 of 2 | 5 | NCT02115256 | Trial comparisons |
| Intravenous Terbutaline vs Intravenous Nitroglycerine: serious adverse events | 0 of 3 | 0 of 2 | 5 | NCT02115256 | Trial comparisons |
Papers from its trials4
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/HP_0001623
GET https://conductscience.org/api/diseases/v1/HP_0001623/targets?page=2